Response by Dr. Rath to the Invitation to Become a Reviewer of the International Journal of Cancer

[Guest guest]

Response by Dr. Rath to the Invitation to Become a Reviewer of

the International Journal of Cancer

http://www4.dr-rath-foundation.org/THE_FOUNDATION/About_Dr_Matthias_Rath/letter_\

zurhausen_2008-aug.html

On August 5, 2008, Dr. Rath received an official invitation from the

Editor-in-chief of the International Journal of Cancer (IJC), Professor Harald

zur Hausen, to become a scientific reviewer for that journal. Prof. zur Hausen

is not only the Editor-in-chief of the IJC, but has served for more than two

decades as head of the German Cancer Research Centre (DKFZ) in Heidelberg,

Germany.

For almost half a century, Prof. zur Hausen has been a prominent voice in the

pharmaceutically-oriented cancer research community. His invitation to Dr. Rath,

a prominent critic of conventional cancer therapies and a pioneer of natural

cancer research, is no coincidence. It reflects the beginning of the

re-orientation of international cancer research to specifically include vitamins

and other micronutrients in the fight against this epidemic.

This re-orientation was brought about by significant advances in micronutrient

research in cancer, a new field of medicine led by Dr. Rath and his research

team (www.dr-rath-research.org).

Realizing the significance of this historic moment, Dr. Rath invited the

International Journal of Cancer and the German Cancer Research Center to join

him – based on the widely available scientific evidence – in a global effort to

largely eliminate cancer as a cause of death in future generations.

Following is the full text of Dr. Rath's letter to the Editor-in-chief of the

International Journal of Cancer:

 

 

Professor Harald zur Hausen

Editor in Chief

International Journal of Cancer

Deutsches Krebsforschungs-Zentrum (DKFZ)

 

August 13, 2008

 

Dear Professor zur Hausen,

On August 5, 2008 I received a letter signed by you inviting me to become a

reviewer for the International Journal of Cancer (IJC) one of the most

influential journals in cancer research. Beside your position as the Editor in

Chief of the IJC, you have been chairman of the board of the German Cancer

Research Centre (DKFZ) in Heidelberg for two decades, one of the world’s leading

cancer research institutions.

In your letter you invite me to review a paper submitted to your journal for

publication, documenting the value of ascorbic acid (vitamin C) in the fight

against cancer. As the primary reason for this invitation to become a reviewer

for your journal you state: “Because of your expertise and experience” in the

field of cancer research. I can only interpret this statement as the official

recognition of the key role of micronutrients in the control of cancers for

which my research team and I have been fighting for more than a decade.

For your entire life you have been a prominent representative of conventional

cancer approaches including toxic chemotherapy, radiotherapy and other

approaches that primarily served one goal: to use the cancer epidemic as a

global market for the pharmaceutical investment business with patented drugs.

For you to contact me – an outspoken critic of these conventional approaches to

cancer and a scientific pioneer for new and natural approaches to cancer – was

no coincidence. Your decision recognizes two important facts: 1. The deadlocks

of pharmaceutically driven approaches to cancer and 2. The compelling

perspectives of micronutrients as powerful preventive and therapeutic agents in

the control of, essentially, all forms of human cancer.

With your letter you recognize the urgent need for a reorientation of cancer

research to specifically include micronutrients in the world-wide fight against

cancer. For that decision you should be commended. At the same time, I am fully

aware that this step was not voluntary but was compelled by the simple fact that

the breathtaking perspective of the natural control of cancer can no longer be

ignored. With the world’s media regularly reporting the potential of vitamins

and other micronutrients in reversing cancer, the dam is broken.

Considering the magnitude of negligence and obstruction towards micronutrients

from the side of pharmaceutical medicine and considering the deadly consequences

of this opposition for millions of cancer patients, your letter marks a turning

point. It is obvious, however, that such a turning point in history cannot be

guided by those who share responsibility for – or have at least tolerated – one

of the darkest chapters in the history of mankind: the medical genocide in

cancer.

In this situation, I have decided to respond to your letter in the form of an

Open Letter to be shared with those most concerned about the way forward: The

millions of cancer patients around the world.

I am addressing you:

* with the authority of the scientists whose discoveries now pave the way for

the natural control of cancer;

 

* with the confidence of one of the world’s leading research teams having paved

the way for the natural control of cancer (www.dr-rath-research.org);

 

* and in full recognition of the historic opportunity that now presents itself

to all mankind: to largely eliminate cancer as a scourge for our children,

grandchildren and all future generations.

 

Before outlining the way forward, I consider it my duty to raise some of the

questions from a consternated and outraged public you and your colleagues will

have to answer in the months to come:

* The first studies that documented the potential value of vitamins in the

fight against cancer were published more than half a century ago, when you were

still a student. Why was this research neglected for decades by pharmaceutical

cancer research? Because vitamins were not patentable?

 

* In the intervening 50 years since the answer of pharmaceutical-oriented

cancer research has been chemotherapy and radiology - therapeutic options of

which the most frequent side-effects are to cause even more cancer. Why did

pharmaceutical-oriented cancer researchers not promote effective and safe

natural alternatives? Because keeping the cancer epidemic alive for 5 decades

brought the drug companies more than a trillion dollars in sales?

 

* For two decades you were the head of the German Cancer Research Centre in

Heidelberg with a total research budget of more than a billion Euros. Much of

this money was public and taxpayer money provided for research in the public

interest, namely to eliminate cancer. However, under your leadership much of

this money was wasted for the development of ever more toxic chemotherapies, or

for questionable vaccines with yet unpredictable side-effects. Why was this

money not used for research with vitamins and other effective and safe cancer

therapies? Who will pay back these hundreds of millions of wasted Euros?

 

* In 1992 you published a research paper in the June 11 edition of the Journal

of the European Molecular Biology Organization (EMBO). The results of your

studies showed that retinoic acid, a form of vitamin A, can inhibit the

development of cervical cancer cells infected with the so-called papillomavirus.

Did you ever inform the public about these important results? Did you conduct

clinical studies to save the lives of cancer patients, many of them young women?

Did you ever stand up when vitamin A was publicly discredited over many years in

the interest of the pharmaceutical industry?

 

* On March 8, 2002, our research institute published the breakthrough in the

field of cancer research showing the potentiating effect of a micronutrient

combination in controlling cancer: “Our research proves that vitamin C, lysine,

proline and specific extracts from green tea (polyphenols) can inhibit the

spread of cancer cells.” To reach not only the scientific and medical community

but also those millions of people directly affected by this disease, we

published these findings on a full page in the world’s largest newspaper, USA

Today. Why didn’t you take this life-saving information and make every effort to

confirm it at your center?

 

* In March 2003, together with researchers from our institute, we organized a

lecture tour through Germany . We selected the five university cities, which are

known to have a special focus in cancer research, among them Heidelberg , where

the DKFZ is located. While the lecture halls were packed with patients, none of

your researchers contacted us to initiate a scientific collaboration. Why?

 

* In 2004, when the pharmaceutical industry and its stakeholders in medicine

and the media launched an unprecedented attack against our natural cancer

research, did you stand up for the scientific facts? What will you tell those

millions of cancer patients who over decades were deliberately misled about the

health benefits of micronutrients? What will you tell the relatives of those

cancer patients who discontinued taking micronutrients as a result of this

misinformation and who paid the ultimate price?

 

* In 2005 our research team sent research results for publication to your

International Journal of Cancer about the strong effects of micronutrients in

skin cancer (melanoma) – a particularly aggressive form of cancer. Instead of

publishing it and sharing this important research with scientists and doctors

around the world, publication was declined without your journal even having

reviewed the data. Why has the International Journal of Cancer for decades

almost exclusively published cancer research directly or indirectly serving the

pharmaceutical investment interests? As the editor in chief of this journal, how

could you let that happen?

 

* In October 2006, I had to stand trial in a Hamburg court for publicly stating

that vitamins and micronutrients help in the fight against cancer and for

defending our research in this field. Because of the strength of our research, I

did not have to go to jail. To the contrary, the judge described us as

“pioneers” for a new era in cancer research. Where were you and your colleagues

from the DKFZ? Did you take positions on the side of science and on behalf of

millions of cancer patients?

 

* That same year, the British Medical Journal (BMJ) a scientific journal

similar in influence to your own, embarked on a global defamation campaign

against vitamin and micronutrient research in cancer. A London court approved a

record fine against the BMJ of GBP 100,000. Did you, as the Editor in Chief of

the International Journal of Cancer, take public positions in this important

debate?

 

While the truth about the life-saving role of micronutrients in the fight

against cancer was obstructed over decades, more than six million cancer

patients worldwide died each year. They paid the ultimate price for the

obstruction of the truth in the interests of the pharmaceutical investment

business with the cancer epidemic. In light of this historic failure it would be

naïve to think that a solution can come from those researchers that were largely

responsible for this tragedy – or at least tolerated it.

 

In the interest of millions of cancer patients I therefore consider it incumbent

upon me to direct the way forward. Here is what needs to be done immediately:

* Dedicate 50% of each future edition of the International Journal of Cancer to

scientific and medical reports in the field of micronutrient research and other

science-based natural health approaches to cancer.

 

* Assure that science-based natural health research is adequately represented

in the International Journal of Cancer by appointing new members to the

editorial board, making sure that they are experts in the field of vitamin and

micronutrient research and that they represent 50% of the members of the new

board.

 

* Appoint researchers from the field of micronutrient research to the governing

bodies of the German Cancer Research Center (DKFZ) and allocate 50% of all

future DKFZ budgets to micronutrient research in cancer.

 

* Help make sure that micronutrient therapies are reimbursed by the health

insurance providers as scientifically proven therapies in the fight against

cancer.

 

In the interest of millions of people, these tasks need to be tackled

immediately. Considering the immense task to redirect cancer research on a

global level, your invitation for me to join your journal as a reviewer is a

drop in the ocean.

I am inviting you and your research colleagues to join us in a vigorous

international effort with the defined goal to end the cancer epidemic forever.

The scientific rationale to reach this goal is available. What needs to be done

now is to organize a global effort to end cancer, involving science, medicine,

politics and all other sectors of society.

With millions of lives at stake, if you stay indifferent now, history will judge

you. If you decide to act, we will join our forces towards this great goal all

mankind has been waiting for. If this is the goal, my research team and I are

ready to cooperate with your journal and your research colleagues at every

level.

As a first step we propose to jointly organize a public symposium between your

journal, the DKFZ and our research institute. At this symposium the best

researchers from the DKFZ and from our research team would present their

research to an audience of patients, doctors and the public at large. Such a

symposium could serve as the beginning of an international campaign carried by

our research institutes and others who will join us towards the eradication of

cancer.

I am looking forward to your response.

Sincerely yours,

 

Matthias Rath, M.D.